ESR1-Guided Endocrine Switching in HR-Positive Metastatic Breast Cancer: From Detection to Risk-Adapted Decision in SERENA-6
Journal of Immunotherapy and Precision Oncology · 23.07.2026 · 9 (3) · 120-123
DOI: 10.36401/jipo-26-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Immunotherapy and Precision Oncology, erschienen am 23.07.2026. Verfasst von Atlal Abusanad. Beteiligte Einrichtung: Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. Die Arbeit nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
- Medical Oncology Division, Department of medicine, King Abdulaziz University Hospital, Jeddah, Saudi Arabia.
ORCID-Profile: Atlal Abusanad
Zitieren
APA
Abusanad, A. (2026). ESR1-Guided Endocrine Switching in HR-Positive Metastatic Breast Cancer: From Detection to Risk-Adapted Decision in SERENA-6. Journal of Immunotherapy and Precision Oncology, 9(3), 120-123. https://doi.org/10.36401/jipo-26-5
Vancouver
Abusanad A. ESR1-Guided Endocrine Switching in HR-Positive Metastatic Breast Cancer: From Detection to Risk-Adapted Decision in SERENA-6. Journal of Immunotherapy and Precision Oncology. 2026;9(3):120-123. doi:10.36401/jipo-26-5
BibTeX
@article{Abusanad2026,
author = {Abusanad, Atlal},
title = {ESR1-Guided Endocrine Switching in HR-Positive Metastatic Breast Cancer: From Detection to Risk-Adapted Decision in SERENA-6},
journal = {Journal of Immunotherapy and Precision Oncology},
year = {2026},
volume = {9},
number = {3},
pages = {120--123},
doi = {10.36401/jipo-26-5}
}
EUVIMED